Neoantigen Cancer Vaccine Market Size & Outlook, 2025-2033

Neoantigen Cancer Vaccine Market Size

The global neoantigen cancer vaccine market size was valued at USD 377.53 million in 2024 and is projected to reach from USD 434.16 million in 2025 to USD 1328.10 million by 2033, growing at a CAGR of 15% during the forecast period (2025-2033).

Neoantigens that arise from cancer-specific mutations are an additional class of antigens that are desirable for therapeutic cancer vaccines. Vaccination against tumour-specific neoantigens reduces the possibility of inducing central and peripheral tolerance, as well as the risk of autoimmunity. Recent preclinical and early-phase clinical studies have demonstrated that cancer vaccines based on neoantigens have significant therapeutic potential.

Cancer vaccines employ weakened or killed viruses, bacteria, or other infection-causing agents to elicit an immune response in the body. These vaccines are intended to have a similar effect, in which the immune system will recognise, attack, and destroy cancer cells. They identify cancer cells as foreign and consequently prime the immune system to attack them. Vaccines against cancer are one way to utilise the immune system to combat cancer.

To get more insights about this report Download Free Sample Report

Market Dynamics

Drivers for the Neoantigen Cancer Vaccine Market

• Huge Investments Drive the Market

The growth of the market for Neoantigen cancer vaccines is primarily attributable to rapid technological advancements and improvements in the healthcare industry's infrastructure. In addition to this, the increasing investments by governments and other healthcare providers are expected to create opportunities for the global neoantigen cancer vaccine market over the next few years.

• Rising Numbers of Cancer Cases

Nowadays, sedentary lifestyles, unhealthy diets, and at times even some sorts of addiction are catering to a rise in numbers of cancer cases. This drives the market for cancer treatment and the Neoantigen Cancer Vaccines. With new research and development now, it can be assured that Cancer can be prevented as well as cured.Moreover, the demand for oncology pharmaceuticals and, it appears, the global Neoantigen Cancer Vaccine market are being driven by increased awareness of particular & effective cancer management treatments worldwide. The pharmaceutical industry has made significant investments in R&D operations to meet the latent and present demand for Neoantigen Cancer Vaccines due to the growing emphasis on individualized cancer therapy and the increasing financial burden associated with cancer treatment procedures.

• Personalised Medicines

As each person’s health conditions are different, and each body’s responses to medicine are different, with the increasing awareness, the adoption of Personalized Medicine to Tailor Patient's Treatment on an Individual Level has increased. This boosts the market for neoantigen cancer vaccine.Personalized cancer vaccines are a revolutionary formulation that calls for identifying the proper antigens in a specific patient before vaccine creation. Due to their excellent specificity and targetability for each disease, tailored vaccinations have recently attracted the most interest from academic institutions, pharmaceutical corporations, and researchers. Because the revolutionary customized cancer vaccine is created based on each person's unique genetic profile, it can overcome the drawback of traditional vaccines, which were effective in just a small subpopulation. Additionally, it lowers the price and likelihood that medications would fail in treating cancer patients. This boosts the market for a neoantigen cancer vaccine.

• Increasing Strategic Partnerships among Major Market Players to Drive Market Growth

The market is characterized by a significant focus on introducing novel vaccines by industry companies like Merck & Co., Inc., GSK plc, and others. However, a sizable market gap is feared due to a lack of product approvals and an imbalance of therapeutic indications in the pipeline for new vaccines. Additionally, small and mid-size biotech businesses and academic institutions working to develop novel cancer vaccines are having trouble finding funding and investments. Therefore, new business structures that encourage collaboration are being adopted so that these businesses may access international markets and provide the market with cutting-edge new items.

Restraints for the Neoantigen Cancer Vaccine Market

• Quite A Costly Process

Although the adoption of personalised medicines acts as a boon for the market, this is quite an expensive process. Moreover, the research & development in this process and its setup also require more considerable investments. This requirement of high capital is restricting the growth of the neoantigen cancer vaccine market.

Opportunities for the Neoantigen Cancer Vaccine Market

• Research and Development Are Predicted to Drive the Market Further

The new research and development are creating a lot of things for the market like reducing treatment gaps, reducing turnaround time and cost etc. This may boost the growth of the market in the near future. Also, the partnership and collaboration between various healthcare stakeholders are creating room for further research and development, which is predicted to drive the market in future.

• Rapid Innovation in the Healthcare Sector

Rapid technological and infrastructure advancements in the healthcare sector are another essential aspect projected to support the growth of the neoantigen cancer vaccine market globally in the upcoming year's increased investments by governing authorities and healthcare providers.

Regional Analysis

Due to the rising prevalence and incidence of lung cancer, melanoma, gastrointestinal, pancreatic cancer, and other solid tumour indications, North America is anticipated to be the leading regional market for neoantigen cancer vaccines over the forecast period. Countries like the United States of America are enriched with good healthcare infrastructure, and they are also investing massive amounts in research and development making them the most dominant regions in the global neoantigen cancer vaccine market.

Due to the increased prevalence and incidence of cancer cases, including lung cancer, melanoma, gastrointestinal, pancreatic, and other solid tumor indications, the Asia Pacific neoantigen cancer vaccine market is anticipated to be the leading region throughout the forecast period.

Segmental Analysis

The global neoantigen cancer vaccine market is segmented on the basis of product, neoantigen type, administration route, cell, technology, delivery mechanism, application, region, and company. The market can be segmented by route of administration into intravenous, intramuscular, transdermal, and other segments. The intravenous segment is anticipated to dominate the market, while the intramuscular segment is projected to grow at the fastest rate during the forecast period. This growth can be attributed to rapid response and the fact that drug dosage can be easily controlled. In addition, intramuscular injections may be used instead of intravenous injections for drugs that cause vein irritation when administered intravenously. This is anticipated to result in substantial growth of the intramuscular route of the administration segment over the next several years.

The application segment is subdivided further into lung, melanoma, digestive, and brain cancers, among others. As the neoantigen-based immunotherapy of OSE Immunotherapeutic, which is in development for the Tedopi (OSE2101) neoantigen cancer vaccine, is expected to launch in 2022, lung cancer will dominate the market during the forecast period. Tedopi (OSE2101) is used to treat patients with HLA-A2+ Non-small cell lung cancer (NSCLC). Currently, the vaccine is in clinical development phase III.

List of key players in Neoantigen Cancer Vaccine Market

1. OSE Immunotherapeutics SA
2. Gritstone bio Inc.
3. BioNTech SE
4. Hoffmann-La Roche Ltd.
5. Pfizer Inc.
6. Merck & Co. Inc.
7. Moderna Inc.
8. Avidea Technologies Inc.
9. Eli Lilly and Company
10. Vaccibody AS
11. Agenus Inc.
12. Novogene Co. Ltd.
13. ZIOPHARM Oncology Inc.
14. ISA Pharmaceuticals B.V.
15. BrightPath Biotherapeutics Co. Ltd.
16. Vaximm AG
17. Medigene AG
18. Genocea Biosciences Inc.
19. Advaxis Inc.
20. Nouscom AG

To get more findings about this report Download Market Share

Recent Developments

• In December 2022, First Patient Dosed with Anti-PD1 Monoclonal Antibody OSE-279 in a Phase 1/2 Clinical Trial in Advanced Solid Tumors or Lymphomas, According to OSE Immunotherapeutics.
• In December 2022, At the American Society of Hematology (ASH) Annual Meeting 2022, OSE Immunotherapeutics will present the most recent preclinical efficacy data on its anti-IL-7 receptor antagonist OSE-127 in acute lymphoblastic leukemia.
• In January 2023, To strengthen its leading position in AI-powered drug discovery, design, and development, BioNTech will acquire InstaDeep.
• In January 2023, Up to 10,000 Patients Will Receive Personalized mRNA Cancer Immunotherapies From BioNTech By 2030, the company said in an announcement with the U.K. government.
• In February 2023, the European Commission expanded Roche's Hemlibra label to encompass Europeans with moderate hemophilia A.